Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...

SUPN insiders have traded $SUPN stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mild cognitive impairment companies ...

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...

The industry is estimated to be USD 58 billion, with equal contributions from exports and domestic market. (Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The hefty tariffs President-elect Trump has pledged to levy on U.S. imports could impact the price and availability of pharmaceutical drugs. Trump has floated 25 percent tariffs on imports from ...

NEW YORK, Dec 31 (Reuters) - Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer (PFE.N), opens new tab COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...

This scenario indicates that 2025 will be a promising year for the pharma sector. A report by Axis Securities last month outlined a positive outlook for the pharmaceutical sector over the next three ...